Orion Corporation, Orion Pharma

Quick facts

Marketed products

• Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI · Immunology
  Bufomix® Easyhaler® combines an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) to reduce inflammation and bronchodilation in the airways.
• Comtess® · Neurology
  Comtess inhibits catechol-O-methyltransferase (COMT), an enzyme that breaks down levodopa, thereby prolonging levodopa's therapeutic effect in the brain.
• Indacaterol/glycopyrronium · Respiratory / Pulmonology
  Indacaterol is a long-acting beta-2 agonist that stimulates airway smooth muscle relaxation, while glycopyrronium is an anticholinergic that blocks muscarinic receptors to further dilate airways.
• Indacaterol maleate and glycopyrronium bromide
• ODM-102 · Other
• ODM-201 Tablet A · Oncology
  ODM-201 is an androgen receptor antagonist that blocks the binding of androgens to the androgen receptor, inhibiting androgen-driven prostate cancer cell growth.
• ODM-203 (Period 1) · Neurology
  ODM-203 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain.
• Placebo Part I
  Placebo produces no pharmacological effect and serves as an inert control or reference standard in clinical research.
• Placebo Part II
  Placebo Part II is an inert substance with no active pharmacological mechanism.
• Placebo Spiriva capsule · Respiratory
  This is a placebo formulation with no active pharmacological mechanism.
• Stalevo · Other
• Ventoline® Evohaler® 100 µg/inhalation pMDI · Respiratory / Pulmonology
  Albuterol (salbutamol) is a short-acting beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow.

Phase 3 pipeline

• Placebo for levosimendan · Cardiovascular
  Levosimendan is a calcium sensitizer that increases cardiac contractility without increasing oxygen demand.
• Symbicort Turbuhaler · Respiratory
  Symbicort Turbuhaler is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic receptor agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).

Phase 2 pipeline

• levodopa MR
• ODM-109
• ODM-201 capsule formulation

Phase 1 pipeline

• 11C-ORM-13070
• Charcoal and Symbicort Turbuhaler
• intravenous14C-ODM-201
• Levodopa, carbidopa, ODM-104
• ODM-104
• ODM-106
• ODM-201 Tablet B
• ODM 203
• ODM-208
• ODM-209
• ODM-212
• ODM103
• ORM-12741 IR
• ORM-12741 MR A
• ORM-12741 MR B
• ORM-14540
• Seretide Diskus
• Seretide Diskus and charcoal
• Seretide Diskus with charcoal
• SF Easyhaler
• SF Easyhaler and charcoal
• Symbicort Turbuhaler forte
• Ultibro Breezhaler with oral charcoal

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Orion Corporation, Orion Pharma portfolio CI brief
• Orion Corporation, Orion Pharma pipeline updates RSS